Status:
COMPLETED
Epidemiology Study of Malaria Transmission Intensity in Africa
Lead Sponsor:
GlaxoSmithKline
Collaborating Sponsors:
The PATH Malaria Vaccine Initiative (MVI)
Conditions:
Malaria
Malaria Vaccines
Eligibility:
All Genders
6+ years
Phase:
NA
Brief Summary
The aim of this epidemiology study is to characterize in a standardized way malaria transmission intensity at the clinical trial centers participating in study 110021 (NCT00866619).
Detailed Description
This study is a multicenter epidemiology study at centers that are participating in GSK's pivotal Phase III candidate malaria vaccine 110021 ( NCT00866619) trial and will involve 4 annual cross sectio...
Eligibility Criteria
Inclusion
- Subjects who the investigator believes that they and/or their parent(s)/Legally Acceptable Representative(s) can and will comply with the requirements of the protocol.
- A male or female 6 months or older at the time of survey.
- Written informed consent obtained from the subject/from the parent(s)/ Legally Acceptable Representative(s) of the subject.
Exclusion
- Child in care.
- Previous or current participation in any malaria vaccine trial.
Key Trial Info
Start Date :
March 14 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 20 2013
Estimated Enrollment :
21618 Patients enrolled
Trial Details
Trial ID
NCT01190202
Start Date
March 14 2011
End Date
December 20 2013
Last Update
August 18 2020
Active Locations (8)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
Ouagadougou, Burkina Faso
2
GSK Investigational Site
Lambaréné, Gabon
3
GSK Investigational Site
Kintampo, Ghana
4
GSK Investigational Site
Kumasi, Ghana